PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Shaw, Alice T.
TI  - Phase 3 Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced ALK-Positive NSCLC
DP  - 2012  01
TA  - MD Conference Express
PG  - 13--14
VI  - 12
IP  - 15
4099  - http://mdc.sagepub.com/content/12/15/13.2.short
4100  - http://mdc.sagepub.com/content/12/15/13.2.full
AB  - Although single-agent second-line chemotherapy has limited efficacy in unselected non-small cell lung cancer (NSCLC), its effect in advanced anaplastic Kinase positive (ALK+) NSCLC is uncertain. Crizotinib has marked clinical activity in ALK+ NSCLC [Camidge DR et al. Lancet Oncol 2012; Kim DW et al. ASCO 2012. Abstract 7533]. The PROFILE 1007 [NCT00932893] trial compared the efficacy and safety of crizotinib with standard chemotherapy as second-line therapy in patients with advanced ALK+ NSCLC.